KeyBanc sees a buying opportunity with Encompass Health (EHC) shares down following a negative New York Times report that focuses on alleged quality deficiencies at its inpatient rehab facilities. The firm does not find the article compelling and believes Encompass’ Q2 report is positioned for a beat. The article reached conclusions by selectively analyzing readmissions data at a subset of Encompass’ facilities, the analyst tells investors in a research note. KeyBanc believes the company has above-average acuity and keeps an Overweight rating on the shares with a $135 price target The stock in afternoon trading is down 10% to $107.87.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health Highlights Financial Measures in New Book
- Encompass Health to build 50-bed inpatient rehabilitation hospital in Nevada
- Encompass Health Updates on 2025 Financial Projections
- BofA says UnitedHealth comments imply some pressure in commercial book of biz
- Encompass Health management to meet with Stephens